CervoMed (CRVO) Price & Analysis

Compare

1,136 Followers

CRVO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.80 - $20.63

Previous CloseN/A

Volume72.82K

Average Volume (3M)597.30K

Market Cap

$86.98M

Enterprise Value$22.72M

Total Cash (Recent Filing)$33.53M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta-0.20

Next Earnings

Nov 18, 2025

EPS Estimate

-0.55

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.70

Shares Outstanding9,252,719

10 Day Avg. Volume220,137

30 Day Avg. Volume597,303

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.26

Enterprise Value/Revenue2.92

Enterprise Value/Gross Profit-2.06

Enterprise Value/Ebitda-0.93

Forecast

1Y Price Target

$19.50

Price Target Upside102.28% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical TrialsImpressive 32-week Phase 2b data bolster neflamapimod's potential in dementia with Lewy bodies.

Financial StabilityCervomed Inc. has a cash runway into mid-2026, providing some financial stability for ongoing and future trials.

Investor ConfidenceNeflamapimod is increasingly gaining investor confidence with the new data from the trial extension phase.

Bears Say

Capital ConstraintsCapital constraints remain the main headwind, and if the FDA requires another randomized Phase 2, there could be pressure on the stock.

Capital RequirementCervomed Inc. will need to raise capital to conduct a Phase 3 program, with a modeled $25 million raise expected on the back of open-label extension data.

Clinical Trial ChallengesIn the randomized Phase 2b trial, the desired plasma drug concentrations were not achieved, and the old capsules acted as a placebo.

CervoMed News

CervoMed price target lowered to $16 from $20 at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on CervoMed (CRVO) to $16 from $20 and...

2d ago

CRVO

CervoMed reports Q2 EPS (70c), consensus (50c)

Reports Q2 revenue $1.758M, consensus $1.13M. “With the reporting of both 16- and 32-week Extension phase data from...

3d ago

CRVO

CervoMed expects cash to fund operations into Q3 of 2026

As of June 30, 2025, CervoMed (CRVO) had approximately $33.5 million in cash, cash equivalents and marketable securities,...

3d ago

CRVO

CervoMed price target raised to $27 from $21 at Canaccord

Canaccord raised the firm’s price target on CervoMed (CRVO) to $27 from $21 and keeps a Buy rating...

16d ago

CRVO

CervoMed announces 32-week data from Extension phase of Phase 2b RewinD-LB

CervoMed (CRVO) announced positive 32-week data from the Extension phase of the Phase 2b RewinD-LB trial showing that...

17d ago

CRVO

CervoMed Reports Promising Trial Results and Financial Update

Cervomed Inc. ( ($CRVO) ) has released its Q2 earnings. Here is a breakdown of the information Cervomed...

3d ago

CRVO

CervoMed Shares Business and Financial Updates Online

CervoMed ( ($CRVO) ) has issued an announcement. CervoMed Inc. has made available certain business, clinical studies, development...

9d ago

CRVO

CervoMed’s Promising Clinical Trial Data and Strategic Focus Boost Buy Rating and Price Target

Soumit Roy, an analyst from JonesTrading, reiterated the Buy rating on CervoMed. The associated price target was raised...

17d ago

CRVO

CervoMed Announces Positive Phase 2b Trial Results

CervoMed ( ($CRVO) ) has shared an update. On July 28, 2025, CervoMed announced positive 32-week data from...

17d ago

CRVO

CervoMed Stockholders Approve Key Proposals at Annual Meeting

CervoMed ( ($CRVO) ) has shared an update. On June 23, 2025, CervoMed Inc. held its Annual Meeting...

2M ago

CRVO

CervoMed appoints Marco Verwijs as EVP, technical operations

CervoMed (CRVO) reported a key senior leadership hire to oversee the Company’s Chemistry, Manufacturing, and Controls division and...

2M ago

CRVO

CervoMed Releases New Business and Financial Information

CervoMed ( ($CRVO) ) has shared an announcement. CervoMed Inc. has made certain business, clinical studies, and financial...

3M ago

CRVO

CervoMed’s Strategic Advancements and Market Opportunities Drive Buy Rating

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on CervoMed (CRVO – Research...

3M ago

CRVO

CervoMed’s Promising Future: Buy Rating Backed by Strong Pipeline and Financial Position

In a report released yesterday, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on CervoMed (CRVO –...

3M ago

CRVO

CRVO FAQ

What was Cervomed Inc.’s price range in the past 12 months?

Cervomed Inc. lowest stock price was $1.80 and its highest was $20.63 in the past 12 months.

What is Cervomed Inc.’s market cap?

Cervomed Inc.’s market cap is $86.98M.

When is Cervomed Inc.’s upcoming earnings report date?

Cervomed Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 96 days.

How were Cervomed Inc.’s earnings last quarter?

Cervomed Inc. released its earnings results on Aug 11, 2025. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.615 by -$0.085.

Is Cervomed Inc. overvalued?

According to Wall Street analysts Cervomed Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cervomed Inc. pay dividends?

Cervomed Inc. does not currently pay dividends.

What is Cervomed Inc.’s EPS estimate?

Cervomed Inc.’s EPS estimate is -0.55.

How many shares outstanding does Cervomed Inc. have?

Cervomed Inc. has 9,252,719 shares outstanding.

What happened to Cervomed Inc.’s price movement after its last earnings report?

Cervomed Inc. reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.615. Following the earnings report the stock price went down -3.553%.

Which hedge fund is a major shareholder of Cervomed Inc.?

Currently, no hedge funds are holding shares in CRVO

CervoMed Stock Smart Score

Outperform

Fundamentals

Return on Equity

-54.21%

Trailing 12-Months

Asset Growth

-28.41%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cervomed Inc.

CervoMed (CRVO) is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of neurodegenerative diseases. The company operates within the healthcare and life sciences sectors, leveraging cutting-edge research and development to address unmet medical needs in conditions such as Alzheimer's disease and other neurological disorders.

CervoMed (CRVO) Earnings & Revenues

Historic Earnings Reports

CRVO Stock 12 Month Forecast

Average Price Target

$19.50

▲(102.28% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","28":"$28","7.75":"$7.75","14.5":"$14.5","21.25":"$21.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$27.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.75,14.5,21.25,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.83,10.227692307692308,11.625384615384615,13.023076923076923,14.420769230769231,15.81846153846154,17.216153846153844,18.613846153846154,20.011538461538464,21.40923076923077,22.806923076923077,24.204615384615387,25.60230769230769,{"y":27,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.83,9.650769230769232,10.471538461538461,11.292307692307693,12.113076923076923,12.933846153846154,13.754615384615384,14.575384615384616,15.396153846153847,16.216923076923077,17.03769230769231,17.85846153846154,18.67923076923077,{"y":19.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.83,9.304615384615385,9.77923076923077,10.253846153846155,10.728461538461538,11.203076923076923,11.677692307692308,12.152307692307692,12.626923076923077,13.10153846153846,13.576153846153847,14.05076923076923,14.525384615384615,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.12,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.38,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.93,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >